Hledání v detailu akcií
Moje portfolio
Nastavit Oblíbené, nastavit Portfolio
Oblíbené tituly
select
NázevNejlepší
nákup
Nejlepší
prodej
Změna
(%)
ČEZ855,5857,50,29
KB765,57660,33
PKN58,4658,48-3,94
Msft437,11437,390,00
Nokia3,7993,8030,50
IBM215,94216,50,00
Mercedes-Benz Group AG58,958,932,26
PFE29,829,820,00
19.09.2024 10:30:44
Indexy online
AD Index online
select
AD Index online
 

  • 18.09.2024
GlycoMimetics (NASDAQ Cons)
Závěr k 18.9.2024 Změna (%) Změna (USD) Objem obchodů (ks)
0,164 -0,61 0,00 1 830 362
Premarket19.09.2024 10:25:50
Poslední obchod Nákup / Prodej Změna (%) Změna (USD) Objem obchodů (ks)
- 0,164 0,17 - - -
R - Real-Time data si mohou aktivovat klienti Patria Plus / Investor Plus ZDE.

 
  • Poslední aktualizace: 19.09.2024
Popis společnosti
Obecné informace
Název společnostiGlycoMimetics Inc
TickerGLYC
Kmenové akcie:Ordinary Shares
RICGLYC.O
ISIN-
Prioritní akciePreference Shares
Poslední známé roční výsledky31.12.2023
Poslední známé čtvrtletní výsledky30.06.2024
Počet zaměstnanců k 31.12.2023 35
Akcie v oběhu k 07.08.2024 64 483 958
MěnaUSD
Kontaktní informace
Ulice9708 Medical Center Drive
MěstoROCKVILLE
PSČ20850
ZeměUnited States
Kontatní osoba 
Funkce kontaktní osoby 
Telefon12 402 431 201
Fax12402431018

Business Summary: GlycoMimetics, Inc. is a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers, including acute myeloid leukemia (AML) and for inflammatory diseases. It is developing a pipeline of glycomimetics, which are small molecules that mimic the structure of carbohydrates involved in biological processes, to inhibit disease-related functions of carbohydrates, such as the roles they play in inflammation, cancer and infection. Its drug candidates include Uproleselan, GMI-1687, Galectin Antagonists and GMI-1359. It is developing Uproleselan, a specific E-selectin antagonist, to be used in combination with chemotherapy to treat patients with AML, a life-threatening hematologic cancer, and potentially other hematologic cancers. It has designed an antagonist of E-selectin, GMI-1687, that is suitable for subcutaneous administration. GMI-1359 is a drug candidate that simultaneously targets both E-selectin and a chemokine receptor (CXCR4).
Financial Summary: BRIEF: For the six months ended 30 June 2024, GlycoMimetics Inc revenues was not reported. Net loss increased 12% to $20.8M. Higher net loss reflects researcg and development expense balanc increase from $4.9M to $11.6M (expense), General & Administrative Expe increase of 31% to $7.1M (expense), General and administrative expense increase of 64% to $2.1M (expense). Basic Earnings per Share excluding Extraordinary Items decreased from -$0.30 to -$0.32.
Odvětvová klasifikace
TRBC2009Biotechnology / Medical Research
TRBC2012Bio Therapeutic Drugs
RBSS2004Biotechnology
MGINDUSTRYBiotechnology & Drugs
MGSECTORHealthcare
NAICSResearch and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
NAICSPharmaceutical Preparation Manufacturing
NAICS2007Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology)
NAICS2007Pharmaceutical Preparation Mfg
NAICS1997Research and Development in the Physical, Engineering, and Life Sciences
NAICS1997Pharmaceutical Preparation Manufacturing
SICPharmaceutical Preparations
SICCommercial Physical Research
SICPharmaceutical Preparations



  • Poslední aktualizace: 19.09.2024
Management společnosti
FunkceJménoVěkVe funkci odVe firmě od
President, Chief Executive Officer, DirectorHarout Semerjian5306.08.202106.08.2021
Co-Founder, DirectorRachel King6406.08.202101.01.2003
Chief Financial Officer, Senior Vice PresidentBrian Hahn49
Senior Vice President, Chief Commercial OfficerBruce Johnson5623.02.202223.02.2022
Senior Vice President, Chief Business OfficerChinmaya Rath48